Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Drops By 50.2%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 13,800 shares, a decline of 50.2% from the October 15th total of 27,700 shares. Based on an average trading volume of 158,500 shares, the short-interest ratio is currently 0.1 days.

Biodexa Pharmaceuticals Trading Down 0.6 %

NASDAQ BDRX traded down $0.03 on Wednesday, hitting $4.99. 7,353 shares of the stock were exchanged, compared to its average volume of 128,166. Biodexa Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $220.25.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.